Bill Text: IA HF2157 | 2023-2024 | 90th General Assembly | Introduced
Bill Title: A bill for an act relating to insurance coverage for biomarker testing.(See HF 2492, HF 2668.)
Spectrum: Partisan Bill (Republican 3-0)
Status: (Introduced - Dead) 2024-03-27 - Withdrawn. H.J. 690. [HF2157 Detail]
Download: Iowa-2023-HF2157-Introduced.html
House
File
2157
-
Introduced
HOUSE
FILE
2157
BY
LOHSE
,
YOUNG
,
and
LUNDGREN
A
BILL
FOR
An
Act
relating
to
insurance
coverage
for
biomarker
testing.
1
BE
IT
ENACTED
BY
THE
GENERAL
ASSEMBLY
OF
THE
STATE
OF
IOWA:
2
TLSB
6095YH
(2)
90
nls/ns
H.F.
2157
Section
1.
NEW
SECTION
.
514C.36
Biomarker
testing
——
1
coverage.
2
1.
As
used
in
this
section,
unless
the
context
otherwise
3
requires:
4
a.
“Biomarker”
means
a
characteristic
that
is
objectively
5
measured
and
evaluated
as
an
indicator
of
normal
biological
6
processes,
pathogenic
processes,
or
pharmacologic
responses
to
7
a
specific
therapeutic
intervention,
including
but
not
limited
8
to
genetic
mutations
or
protein
expression.
9
b.
“Biomarker
testing”
means
the
analysis
of
an
individual’s
10
tissue,
blood,
or
other
biospecimen
for
the
presence
of
a
11
biomarker,
including
but
not
limited
to
single-analyte
tests,
12
multiplex
panel
tests,
or
whole
genome
sequencing.
13
c.
“Clinical
utility”
means
sufficient
medical
and
14
scientific
evidence
indicating
the
use
of
a
specific
biomarker
15
test
will
provide
meaningful
information
that
will
affect
16
treatment
decisions
and
improve
a
covered
person’s
outcome.
17
d.
“Consensus
statement”
means
a
statement
developed
by
18
an
independent,
multidisciplinary
panel
of
experts,
none
of
19
whom
have
a
conflict
of
interest,
who
utilize
a
transparent
20
methodology
and
reporting
structure.
A
consensus
statement
21
concerns
specific
clinical
circumstances
and
is
based
on
the
22
best
available
evidence
for
the
purpose
of
optimizing
the
23
outcomes
of
clinical
care.
24
e.
“Covered
person”
means
a
policyholder,
subscriber,
or
25
other
person
participating
in
a
policy,
contract,
or
plan
that
26
provides
for
third-party
payment
or
prepayment
of
health
or
27
medical
expenses.
28
f.
“Health
care
professional”
means
the
same
as
defined
in
29
section
514J.102.
30
g.
“Local
coverage
determinations”
means
the
same
as
defined
31
in
section
1869(f)(2)(B)
of
the
federal
Social
Security
Act.
32
h.
“National
coverage
determinations”
means
the
same
as
33
defined
in
section
1869(f)(1)(B)
of
the
federal
Social
Security
34
Act.
35
-1-
LSB
6095YH
(2)
90
nls/ns
1/
4
H.F.
2157
i.
“Nationally
recognized
clinical
practice
guidelines”
1
means
evidence-based
clinical
practice
guidelines
developed
by
2
independent
organizations
or
medical
professional
societies,
3
none
of
which
have
a
conflict
of
interest,
that
utilize
a
4
transparent
methodology
and
reporting
structure.
Clinical
5
practice
guidelines
establish
standards
of
care
informed
6
by
a
systematic
review
of
evidence
and
assessment
of
the
7
costs
and
benefits
of
alternative
care
options
and
include
8
recommendations
intended
to
optimize
patient
care.
9
2.
Notwithstanding
the
uniformity
of
treatment
requirements
10
of
section
514C.6,
a
policy,
contract,
or
plan
providing
for
11
third-party
payment
or
prepayment
of
medical
expenses
shall
12
provide
coverage
for
biomarker
testing
for
the
purposes
of
13
diagnosing,
treating,
appropriately
managing,
or
monitoring
14
cancer
in
a
covered
person
when
the
biomarker
testing
has
15
demonstrated
clinical
utility,
including
but
not
limited
to
any
16
of
the
following:
17
a.
Labeled
indications
for
a
test
approved
or
cleared
by
18
the
United
States
food
and
drug
administration
or
indicated
19
tests
for
a
drug
approved
by
the
United
States
food
and
drug
20
administration.
21
b.
Centers
for
Medicare
and
Medicaid
services
of
the
22
United
States
department
of
health
and
human
services
national
23
coverage
determinations
or
Medicare
administrative
contractor
24
local
coverage
determinations.
25
c.
Nationally
recognized
clinical
practice
guidelines
and
26
consensus
statements.
27
3.
Coverage
required
under
this
section
shall
limit
28
disruptions
in
care,
including
mitigating
the
need
for
a
29
covered
person
to
undergo
multiple
biopsies
or
to
provide
30
multiple
biospecimen
samples.
31
4.
A
covered
person
and
the
covered
person’s
health
care
32
professional
shall
have
access
to
a
clear
and
convenient
33
process
available
on
the
health
carrier’s
internet
site
to
34
request
an
exception
to
coverage
provided
under
this
section.
35
-2-
LSB
6095YH
(2)
90
nls/ns
2/
4
H.F.
2157
5.
a.
This
section
applies
to
the
following
classes
of
1
third-party
payment
provider
policies,
contracts,
or
plans
2
delivered,
issued
for
delivery,
continued,
or
renewed
in
this
3
state
on
or
after
January
1,
2025:
4
(1)
Individual
or
group
accident
and
sickness
insurance
5
providing
coverage
on
an
expense-incurred
basis.
6
(2)
An
individual
or
group
hospital
or
medical
service
7
contract
issued
pursuant
to
chapter
509,
514,
or
514A.
8
(3)
An
individual
or
group
health
maintenance
organization
9
contract
regulated
under
chapter
514B.
10
(4)
A
plan
established
pursuant
to
chapter
509A
for
public
11
employees.
12
b.
This
section
shall
apply
to
all
of
the
following:
13
(1)
The
medical
assistance
program
under
chapter
249A.
14
(2)
The
healthy
and
well
kids
in
Iowa
(Hawki)
program
under
15
chapter
514I.
16
(3)
A
managed
care
organization
acting
pursuant
to
a
17
contract
with
the
department
of
health
and
human
services
under
18
chapter
249A,
or
with
the
healthy
and
well
kids
in
Iowa
(Hawki)
19
program
under
chapter
514I.
20
c.
This
section
shall
not
apply
to
accident-only,
21
specified
disease,
short-term
hospital
or
medical,
hospital
22
confinement
indemnity,
credit,
dental,
vision,
Medicare
23
supplement,
long-term
care,
basic
hospital
and
medical-surgical
24
expense
coverage
as
defined
by
the
commissioner,
disability
25
income
insurance
coverage,
coverage
issued
as
a
supplement
26
to
liability
insurance,
workers’
compensation
or
similar
27
insurance,
or
automobile
medical
payment
insurance.
28
6.
The
commissioner
of
insurance
may
adopt
rules
pursuant
to
29
chapter
17A
to
administer
this
section.
30
EXPLANATION
31
The
inclusion
of
this
explanation
does
not
constitute
agreement
with
32
the
explanation’s
substance
by
the
members
of
the
general
assembly.
33
This
bill
relates
to
health
insurance
coverage
for
biomarker
34
testing.
35
-3-
LSB
6095YH
(2)
90
nls/ns
3/
4
H.F.
2157
The
bill
defines
“biomarker
testing”
as
an
analysis
of
1
an
individual’s
tissue,
blood,
or
other
biospecimen
for
the
2
presence
of
a
biomarker.
“Biomarker”
is
also
defined
in
the
3
bill.
4
The
bill
requires
a
health
carrier
that
offers
individual,
5
group,
or
small
group
contracts,
policies,
or
plans
in
this
6
state
that
provide
for
third-party
payment
or
prepayment
of
7
health
or
medical
expenses
to
offer
coverage
for
biomarker
8
testing
for
purposes
of
diagnosing,
treating,
appropriately
9
managing,
or
monitoring
cancer
in
a
covered
person
when
the
10
test
has
demonstrated
clinical
utility
as
detailed
in
the
bill.
11
“Clinical
utility”
is
defined
in
the
bill.
Coverage
shall
be
12
provided
in
a
manner
which
limits
disruptions
in
a
person’s
13
care.
The
bill
requires
a
health
carrier
to
provide
a
process
14
on
its
internet
site
for
a
person
and
the
person’s
health
care
15
professional
to
seek
an
exception
to
coverage
required
under
16
the
bill.
17
The
bill
applies
to
third-party
payment
provider
contracts,
18
policies,
or
plans
delivered,
issued
for
delivery,
continued,
19
or
renewed
in
this
state
on
or
after
January
1,
2025,
by
the
20
third-party
payment
providers
enumerated
in
the
bill.
The
bill
21
specifies
the
types
of
specialized
health-related
insurance
22
which
are
not
subject
to
the
bill’s
coverage
requirements.
23
The
bill
applies
to
the
medical
assistance
program
24
under
Code
chapter
249A,
the
healthy
and
well
kids
in
Iowa
25
(Hawki)
program
under
Code
chapter
514I,
and
a
managed
care
26
organization
acting
pursuant
to
a
contract
with
the
department
27
of
health
and
human
services
to
administer
either
the
medical
28
assistance
program
or
the
Hawki
program.
29
The
commissioner
of
insurance
may
adopt
rules
to
administer
30
the
bill.
31
-4-
LSB
6095YH
(2)
90
nls/ns
4/
4